Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ROCKET PHARMACEUTICALS, INC.ITEK · Entity 5627 | Director | June 20, 2017 | June 21, 2017 |
| TherapeuticsMD, Inc.TXMD · Entity 7541 | Director | August 10, 2021 | August 13, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ROCKET PHARMACEUTICALS, INC.
Report date June 20, 2017 · Filed June 21, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.80 · Expires 2027-06-19 | Direct | 45,000 |
Reported balance
After 2017-06-20 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2017-06-20 · Grant · Acquired 45,000 · Balance 45,000 F1: This stock option award was issued pursuant to Inotek Pharmaceuticals Corporation's 2014 Stock Option and Incentive Plan. The option shall vest in equal quarterly installments at the end of each quarter following June 20, 2017, subject to continued service through such dates. |
Filing footnotes · ownership attribution and instrument terms
F1: This stock option award was issued pursuant to Inotek Pharmaceuticals Corporation's 2014 Stock Option and Incentive Plan. The option shall vest in equal quarterly installments at the end of each quarter following June 20, 2017, subject to continued service through such dates.
TherapeuticsMD, Inc.
Report date August 10, 2021 · Filed August 13, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 106,864 |
Reported balance
After 2021-08-10 transaction · row 1
1 source rowRow 1 · 2021-08-10 · Exercise / conversion · Acquired 96,864 · Balance 106,864 F1: On August 10, 2021, the reporting person received 96,864 shares of common stock of the issuer in settlement of restricted stock units (RSUs), which vested on June 18, 2021. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2021-08-10 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-08-10 · Exercise / conversion · Disposed 96,864 · Balance 0 F1: On August 10, 2021, the reporting person received 96,864 shares of common stock of the issuer in settlement of restricted stock units (RSUs), which vested on June 18, 2021. F2: Each RSU represented a contingent right to receive one share of issuer common stock upon settlement. F3: The RSUs vested on June 18, 2021. |
Filing footnotes · ownership attribution and instrument terms
F1: On August 10, 2021, the reporting person received 96,864 shares of common stock of the issuer in settlement of restricted stock units (RSUs), which vested on June 18, 2021.
F2: Each RSU represented a contingent right to receive one share of issuer common stock upon settlement.
F3: The RSUs vested on June 18, 2021.
Past disclosures · reporting ended (3)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Catalent, Inc.
Report date December 18, 2024 · Filed December 18, 2024
Section 16 reporting ended · disclosed 2024-12-18. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2024-12-18 transaction · row 1
1 source rowRow 1 · 2024-12-18 · Disposition to issuer · Disposed 32,734 · Balance 0 F1: On December 18, 2024, Creek Parent, Inc., a Delaware corporation ("Parent"), acquired the Issuer pursuant to that certain Agreement and Plan of Merger entered into by and among the Issuer, Parent and Creek Merger Sub, Inc., a Delaware corporation and a wholly owned Subsidiary of Parent ("Merger Sub"), dated as of February 5, 2024 (the "Merger Agreement"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer, with the Issuer surviving such merger as a wholly-owned subsidiary of Parent (the "Merger"). F2: Includes restricted stock units ("RSUs"). F3: At the effective time of the Merger (the "Effective Time"), each outstanding share of the Issuer's common stock (other than certain excluded shares) automatically converted into the right to receive $63.50 in cash, without interest (the "Merger Consideration"). F4: At the Effective Time, each RSU, whether or not vested, outstanding immediately prior to the Effective Time vested (if unvested) and was cancelled and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the total number of shares of Issuer common stock subject to the RSU multiplied by (ii) the Merger Consideration, except for certain RSUs granted following the date of the Merger Agreement which were converted at the Effective Time into restricted cash awards equal to the product of (a) the Merger Consideration multiplied by (b) the number of shares of Issuer common stock subject to such award and otherwise remain subject to their terms, including vesting and acceleration terms. |
Filing footnotes · ownership attribution and instrument terms
F1: On December 18, 2024, Creek Parent, Inc., a Delaware corporation ("Parent"), acquired the Issuer pursuant to that certain Agreement and Plan of Merger entered into by and among the Issuer, Parent and Creek Merger Sub, Inc., a Delaware corporation and a wholly owned Subsidiary of Parent ("Merger Sub"), dated as of February 5, 2024 (the "Merger Agreement"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer, with the Issuer surviving such merger as a wholly-owned subsidiary of Parent (the "Merger").
F2: Includes restricted stock units ("RSUs").
F3: At the effective time of the Merger (the "Effective Time"), each outstanding share of the Issuer's common stock (other than certain excluded shares) automatically converted into the right to receive $63.50 in cash, without interest (the "Merger Consideration").
F4: At the Effective Time, each RSU, whether or not vested, outstanding immediately prior to the Effective Time vested (if unvested) and was cancelled and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the total number of shares of Issuer common stock subject to the RSU multiplied by (ii) the Merger Consideration, except for certain RSUs granted following the date of the Merger Agreement which were converted at the Effective Time into restricted cash awards equal to the product of (a) the Merger Consideration multiplied by (b) the number of shares of Issuer common stock subject to such award and otherwise remain subject to their terms, including vesting and acceleration terms.
Esperion Therapeutics, Inc.
Report date July 13, 2026 · Filed July 13, 2026
Section 16 reporting ended · disclosed 2026-07-13. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2026-07-13 transaction · row 1
1 source rowRow 1 · 2026-07-13 · Disposition to issuer · Disposed 177,523 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated May 1, 2026, by and among the Issuer, Essence Parent Inc., a Delaware corporation ("Parent") and Essence MergerCo Inc., a Delaware corporation and wholly owned subsidiary of Parent ("MergerCo"), pursuant to which, on July 13, 2026 (the "Effective Time"), MergerCo merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent. F2: At the Effective Time, each share of the Issuer's common stock, par value $0.001 per share ("Common Stock") was converted into the right to receive (a) an amount in cash equal to $3.16 per share, without interest (the "per share cash consideration"), and (b) one contractual contingent value right per share (each, a "CVR" and, together with the per share cash consideration, the "merger consideration"), representing the right to participate in contingent payments in cash, without interest, upon the achievement of certain milestones, subject to any applicable withholding taxes. From and after the Effective Time, all such shares of Common Stock were no longer outstanding and were automatically canceled. F3: Includes 79,873 restricted stock units (each, a "RSU"). At the Effective Time, each RSU with respect to Common Stock outstanding immediately prior to the Effective Time vested in full (to the extent then-unvested), and was canceled and converted into the right to receive, with respect to each share of Common Stock subject to such RSU immediately prior to the effective time, (a) a cash payment (rounded down to the nearest cent), without interest and subject to applicable tax withholding and deductions, equal to the per share cash consideration, plus (b) one CVR, subject to certain exceptions. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.37 · Expires 2033-06-15 | Direct | 0 |
Reported balance
After 2026-07-13 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-07-13 · Disposition to issuer · Disposed 21,000 · Balance 0 F4: At the Effective Time, each stock option having a per share exercise price that was less than the per share cash consideration (each, an "in-the-money option") was canceled and converted into the right to receive, for each share of Common Stock issuable upon the exercise of such in-the-money option immediately prior to the Effective Time, (a) a cash payment (rounded down to the nearest cent), without interest and subject to applicable tax withholding and deductions, equal to the excess of the per share cash consideration over the per share exercise price of such in-the-money option plus (b) one CVR. F1: This Form 4 reports securities disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated May 1, 2026, by and among the Issuer, Essence Parent Inc., a Delaware corporation ("Parent") and Essence MergerCo Inc., a Delaware corporation and wholly owned subsidiary of Parent ("MergerCo"), pursuant to which, on July 13, 2026 (the "Effective Time"), MergerCo merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.25 · Expires 2034-05-23 | Direct | 0 |
Reported balance
After 2026-07-13 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-07-13 · Disposition to issuer · Disposed 32,500 · Balance 0 F4: At the Effective Time, each stock option having a per share exercise price that was less than the per share cash consideration (each, an "in-the-money option") was canceled and converted into the right to receive, for each share of Common Stock issuable upon the exercise of such in-the-money option immediately prior to the Effective Time, (a) a cash payment (rounded down to the nearest cent), without interest and subject to applicable tax withholding and deductions, equal to the excess of the per share cash consideration over the per share exercise price of such in-the-money option plus (b) one CVR. F1: This Form 4 reports securities disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated May 1, 2026, by and among the Issuer, Essence Parent Inc., a Delaware corporation ("Parent") and Essence MergerCo Inc., a Delaware corporation and wholly owned subsidiary of Parent ("MergerCo"), pursuant to which, on July 13, 2026 (the "Effective Time"), MergerCo merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.87 · Expires 2035-05-29 | Direct | 0 |
Reported balance
After 2026-07-13 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-07-13 · Disposition to issuer · Disposed 44,000 · Balance 0 F4: At the Effective Time, each stock option having a per share exercise price that was less than the per share cash consideration (each, an "in-the-money option") was canceled and converted into the right to receive, for each share of Common Stock issuable upon the exercise of such in-the-money option immediately prior to the Effective Time, (a) a cash payment (rounded down to the nearest cent), without interest and subject to applicable tax withholding and deductions, equal to the excess of the per share cash consideration over the per share exercise price of such in-the-money option plus (b) one CVR. F1: This Form 4 reports securities disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated May 1, 2026, by and among the Issuer, Essence Parent Inc., a Delaware corporation ("Parent") and Essence MergerCo Inc., a Delaware corporation and wholly owned subsidiary of Parent ("MergerCo"), pursuant to which, on July 13, 2026 (the "Effective Time"), MergerCo merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated May 1, 2026, by and among the Issuer, Essence Parent Inc., a Delaware corporation ("Parent") and Essence MergerCo Inc., a Delaware corporation and wholly owned subsidiary of Parent ("MergerCo"), pursuant to which, on July 13, 2026 (the "Effective Time"), MergerCo merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent.
F2: At the Effective Time, each share of the Issuer's common stock, par value $0.001 per share ("Common Stock") was converted into the right to receive (a) an amount in cash equal to $3.16 per share, without interest (the "per share cash consideration"), and (b) one contractual contingent value right per share (each, a "CVR" and, together with the per share cash consideration, the "merger consideration"), representing the right to participate in contingent payments in cash, without interest, upon the achievement of certain milestones, subject to any applicable withholding taxes. From and after the Effective Time, all such shares of Common Stock were no longer outstanding and were automatically canceled.
F3: Includes 79,873 restricted stock units (each, a "RSU"). At the Effective Time, each RSU with respect to Common Stock outstanding immediately prior to the Effective Time vested in full (to the extent then-unvested), and was canceled and converted into the right to receive, with respect to each share of Common Stock subject to such RSU immediately prior to the effective time, (a) a cash payment (rounded down to the nearest cent), without interest and subject to applicable tax withholding and deductions, equal to the per share cash consideration, plus (b) one CVR, subject to certain exceptions.
F4: At the Effective Time, each stock option having a per share exercise price that was less than the per share cash consideration (each, an "in-the-money option") was canceled and converted into the right to receive, for each share of Common Stock issuable upon the exercise of such in-the-money option immediately prior to the Effective Time, (a) a cash payment (rounded down to the nearest cent), without interest and subject to applicable tax withholding and deductions, equal to the excess of the per share cash consideration over the per share exercise price of such in-the-money option plus (b) one CVR.
Keenova Therapeutics plc
Report date June 16, 2022 · Filed June 21, 2022
Section 16 reporting ended · disclosed 2022-06-21. Current position is not established by this disclosure.
No balance rows disclosed in this filing.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 23, 2018 Filed Aug 24, 2018 18:46 UTC | Catalent, Inc. CTLT · Entity 16279 | GrantCommon Stock | 4,183 | $0.00 | $0.00 |
DisclosureSEC source: 0001596783-18-000065 · wf-form4_153513640309017.xml · nonDerivative · entry 1 CARROLL J MARTIN · CIK 0001279901 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,682 F1 · kind: The equity acquired by the reporting person is the regular, annual grant of restricted stock units provided by the Issuer to the reporting person pursuant to the Issuer's non-management director compensation program. Each restricted stock unit represents the right to receive one share of the Issuer's common stock as of the date of vesting, which will occur one year from the date of award. F2 · balance_after: Includes restricted stock units. Read SEC document |
| July 02, 2018 Filed Jul 5, 2018 21:00 UTC | TherapeuticsMD, Inc. TXMD · Entity 7541 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $6.35 | $0.00 |
DisclosureSEC source: 0001387131-18-003026 · carroll-form4_070218.xml · derivative · entry 1 CARROLL J MARTIN · CIK 0001279901 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2028-07-02 Read SEC document |
| June 04, 2018 Filed Feb 5, 2019 13:05 UTC | Keenova Therapeutics plc MNK · Entity 28960 | GiftOrdinary Shares | 20,487 | $0.00 | $0.00 |
DisclosureSEC source: 0000950138-19-000062 · edgar.xml · nonDerivative · entry 4 CARROLL J MARTIN · CIK 0001279901 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 20,487 Read SEC document |
| June 04, 2018 Filed Feb 5, 2019 13:05 UTC | Keenova Therapeutics plc MNK · Entity 28960 | GiftOrdinary Shares | 20,487 | $0.00 | $0.00 |
DisclosureSEC source: 0000950138-19-000062 · edgar.xml · nonDerivative · entry 3 CARROLL J MARTIN · CIK 0001279901 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 0 Read SEC document |
| May 31, 2018 Filed Feb 5, 2019 13:05 UTC | Keenova Therapeutics plc MNK · Entity 28960 | GiftOrdinary Shares | 20,487 | $0.00 | $0.00 |
DisclosureSEC source: 0000950138-19-000062 · edgar.xml · nonDerivative · entry 2 CARROLL J MARTIN · CIK 0001279901 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 20,487 Read SEC document |
| May 31, 2018 Filed Feb 5, 2019 13:05 UTC | Keenova Therapeutics plc MNK · Entity 28960 | GiftOrdinary Shares | 20,487 | $0.00 | $0.00 |
DisclosureSEC source: 0000950138-19-000062 · edgar.xml · nonDerivative · entry 1 CARROLL J MARTIN · CIK 0001279901 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,438 F1 · balance_after: Includes 131 shares distributed in satisfaction of an annuity by the grantor retained annuity trust to the reporting person, which was exempt from reporting pursuant to Rule 16a-13. Read SEC document |
| May 16, 2018 Filed May 18, 2018 20:28 UTC | Keenova Therapeutics plc MNK · Entity 28960 | GrantOrdinary Shares | 18,947 | $0.00 | $0.00 |
DisclosureSEC source: 0000950138-18-000419 · edgar.xml · nonDerivative · entry 1 CARROLL J MARTIN · CIK 0001279901 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,794 F1 · shares: Consists of restricted stock units that vest in their entirety as of the date of the Company's 2019 Annual General Meeting. The restricted stock units settle in ordinary shares upon vesting. Read SEC document |
| March 01, 2018 Filed Mar 5, 2018 21:50 UTC | Keenova Therapeutics plc MNK · Entity 28960 | Tax withholdingOrdinary Shares | 2,576 | $15.68 | $40,391.68 |
DisclosureSEC source: 0000950138-18-000226 · edgar.xml · nonDerivative · entry 1 CARROLL J MARTIN · CIK 0001279901 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,847 Read SEC document |
| November 09, 2017 Filed Nov 13, 2017 21:17 UTC | Keenova Therapeutics plc MNK · Entity 28960 | PurchaseOrdinary Shares | 5,000 | $20.42 | $102,093.50 |
DisclosureSEC source: 0000950138-17-000754 · edgar.xml · nonDerivative · entry 1 CARROLL J MARTIN · CIK 0001279901 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,423 F1 · price: The price represents a weighted average. The shares were purchased in multiple transactions at prices ranging from $20.39 to $20.46, inclusive. Mr. Carroll will provide, upon request of the SEC staff, Mallinckrodt plc or a shareholder of Mallinckrodt plc complete information regarding the number of shares purchased at each price within the range. Read SEC document |
| October 01, 2017 Filed Oct 3, 2017 21:04 UTC | Keenova Therapeutics plc MNK · Entity 28960 | Tax withholdingOrdinary Shares | 476 | $37.37 | $17,788.12 |
DisclosureSEC source: 0000950138-17-000703 · edgar.xml · nonDerivative · entry 1 CARROLL J MARTIN · CIK 0001279901 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,423 F1 · balance_after: Includes 9,458 shares which were contributed by the reporting person to a grantor retained annuity trust in August 2016 and 9,327 shares distributed in satisfaction of an annuity by the grantor retained annuity trust to the reporting person in September 2017. These transactions were exempt from reporting pursuant to Rule 16a-13. Read SEC document |
| August 24, 2017 Filed Aug 28, 2017 15:30 UTC | Catalent, Inc. CTLT · Entity 16279 | GrantCommon Stock | 3,976 | $0.00 | $0.00 |
DisclosureSEC source: 0001596783-17-000125 · wf-form4_150393421613453.xml · nonDerivative · entry 1 CARROLL J MARTIN · CIK 0001279901 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,499 F1 · kind: The equity acquired by the reporting person is the regular, annual grant of restricted stock units provided by the Issuer to the reporting person pursuant to the Issuer's non-management director compensation package adopted in 2014. Each restricted stock unit represents the right to receive one share of the Issuer's common stock as of the date of vesting, which will occur one (1) year from the date of award. F2 · balance_after: Includes restricted stock units. Read SEC document |
| June 21, 2017 Filed Jun 23, 2017 20:31 UTC | TherapeuticsMD, Inc. TXMD · Entity 7541 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $5.80 | $0.00 |
DisclosureSEC source: 0001387131-17-003412 · carroll-form4_062117.xml · derivative · entry 1 CARROLL J MARTIN · CIK 0001279901 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2027-06-21 Read SEC document |
| June 20, 2017 Filed Jun 21, 2017 20:05 UTC | ROCKET PHARMACEUTICALS, INC. ITEK · Entity 5627 | GrantStock Options (Right to Buy) · Derivative | 45,000 | $0.00 Strike: $1.80 | $0.00 |
DisclosureSEC source: 0000899243-17-016835 · doc4.xml · derivative · entry 1 CARROLL J MARTIN · CIK 0001279901 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 45,000 shares Expires 2027-06-19 F1 · derivative.exercise_date: This stock option award was issued pursuant to Inotek Pharmaceuticals Corporation's 2014 Stock Option and Incentive Plan. The option shall vest in equal quarterly installments at the end of each quarter following June 20, 2017, subject to continued service through such dates. Read SEC document |
| March 01, 2017 Filed Mar 4, 2017 00:05 UTC | Keenova Therapeutics plc MNK · Entity 28960 | Tax withholdingOrdinary Shares | 2,286 | $51.55 | $117,843.30 |
DisclosureSEC source: 0000950138-17-000270 · edgar.xml · nonDerivative · entry 2 CARROLL J MARTIN · CIK 0001279901 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,030 Read SEC document |
| March 01, 2017 Filed Mar 4, 2017 00:05 UTC | Keenova Therapeutics plc MNK · Entity 28960 | GrantOrdinary Shares | 5,723 | $0.00 | $0.00 |
DisclosureSEC source: 0000950138-17-000270 · edgar.xml · nonDerivative · entry 1 CARROLL J MARTIN · CIK 0001279901 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,316 F1 · shares: Consists of restricted stock units that vest in their entirety as of March 1, 2018. The restricted stock units settle in ordinary shares upon vesting. Read SEC document |
| December 21, 2016 Filed Dec 23, 2016 00:11 UTC | TherapeuticsMD, Inc. TXMD · Entity 7541 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $5.68 | $0.00 |
DisclosureSEC source: 0001387131-16-008709 · carroll-form4_12212016.xml · derivative · entry 1 CARROLL J MARTIN · CIK 0001279901 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2026-12-20 Read SEC document |
| October 01, 2016 Filed Oct 4, 2016 12:55 UTC | Keenova Therapeutics plc MNK · Entity 28960 | GrantOrdinary Shares | 1,057 | $0.00 | $0.00 |
DisclosureSEC source: 0000950138-16-001369 · edgar.xml · nonDerivative · entry 1 CARROLL J MARTIN · CIK 0001279901 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,593 F1 · shares: Consists of restricted stock units that vest in their entirety as of October 1, 2017. The restricted stock units settle in ordinary shares upon vesting. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.